# US 2013/0260422 A1 · Compositions and Methods Relating to Variant DNA Polymerases and Synthetic DNA Polymerases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0260422 A1
- Document ID: US20130260422A1
- Status: Published application
- Kind: A1
- Application number: 13/823,811
- Filed: 2012-08-31
- Published: 2013-10-03
- Earliest claimed: 2011-09-01
- Assignees: New England Biolabs, Inc.
- Inventors: Jennifer Ong; Thomas C. Evans; Nathan Tanner
- Web page: https://patentgrep.com/patent/US20130260422A1

## CPC

- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Compositions of novel polymerase variants and methods of identifying, making and using these novel polymerases are described. The variants have been shown to have advantageous properties such as increased thermostability, deoxyuridine nucleoside triphosphate tolerance, salt tolerance, reaction speed and/or increased reverse transcriptase properties. Uses for these improved enzymes have been demonstrated in isothermal amplification such as LAMP. Enhanced performance resulting from the use of these variants in amplification has been demonstrated both in reaction vessels and in dedicated automated amplification platforms.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A variant Family A DNA polymerase comprising two or more amino acid sequence motifs selected from 3 . . . EEK . . . 5, 15 . . . ADE . . . 17, 65 . . . SPQ . . . 67, 86 . . . RAI . . . 88, 185 . . . LTE . . . 187, 186 . . . TEL . . . 188, 222 . . . LKE . . . 224, 306 . . . VHP . . . 308, 314 . . . HTR . . . 316, 555 . . . LCK . . . 557, 556 . . . CKL . . . 558 and 567 . . . VEL . . . 569, where the number preceding the amino acid in the motif corresponds to the location of that amino acid in the amino acid sequence of FIG. 1.

### Claim 52 (depends on 51)

A variant polymerase according to claim 51, comprising at least three or four or five or six or seven or eight or nine or ten or eleven or twelve of said motifs.

### Claim 53 (depends on 51)

A variant polymerase according to claim 51, further comprising one or more mutations selected from the group of mutations consisting of (a)-(f) where the mutations in (a)-(f) are:
(a) A1E, G3(K, E or D), K5(L, A or V), E8(M or A), E9D, M10I, A13(D, E, T or V), I14D, V15A, V17(T, E or G), I18V;
(b) E20(M or D) M34(Q or L), E36D, I46F, L48(N or I), M57(L or I), P59(T or A), T61L, D65S, S66(F, E or P);
(c) Q67A, L69(V or K), A73E, M81V, A84R, V88(A or I), R99V, A102D, N113A, D117(T, S or A), A118D, G119(D or E), I121(A or V), V124K, E131H, S135(E or P), V144A, S147(P or A), L148(D or V), Q152(L or P);
(d) T153(A or V), Q170(R or E), M173(L or I), D175E, N178(E, K or R), Q183(L, E or R), L185F, T186(L or I), K187(E or D), Q190(L or M);
(e) A193(I or S), A194(L, S or T), N205(D or K), S216(L or E), R223(V, K or G), A224E, I225(Q or V), V247L, R307H, M316R; and
(f) A330T, D357L, D378N, D380E, I383A, Q387R, L390M; 1400V, E406D, A410S, N411R, A433S, N437G, T439K, A452E, Q459(R or E), N463(V, E or D), L484D, D486E, V494L, T501M, Q530R, I552M, E557(K, Q or R) and T568(E or R).

### Claim 54 (depends on 53)

A variant polymerase according to claim 53, comprising at least one mutated amino acid selected from each of groups (a)-(f).

### Claim 55 (depends on 53)

A variant polymerase of claim 53, further comprising two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty mutant amino acids at the same position as the corresponding amino acids in (a)-(f) of SEQ ID NO:1.

### Claim 56 (depends on 51)

A variant polymerase according to claim 51, wherein a binding domain is fused to one end of the variant polymerase directly or by means of a linker sequence.

### Claim 57 (depends on 53)

A variant polymerase according to claim 53, wherein a binding domain is fused to one end of the variant polymerase directly or by means of a linker sequence.

### Claim 58 (depends on 51)

A DNA encoding a variant polymerase according to claim 51.

### Claim 59 (depends on 53)

A DNA encoding a variant polymerase according to claim 53.

### Claim 60 (depends on 58)

A host cell comprising the DNA according to claim 58.

### Claim 61 (depends on 59)

A host cell comprising the DNA according to claim 59.

### Claim 62 (depends on 53)

A method for reverse transcribing an RNA of interest, comprising combining an RNA with a DNA polymerase variant or preparation thereof according to claim 53, to form a cDNA.

### Claim 63 (depends on 62)

A method according to claim 62, further comprising amplifying the cDNA by means of the DNA polymerase variant or preparation thereof.

### Claim 64 (depends on 53)

A method for amplifying DNA, comprising combining a target DNA with a DNA polymerase variant or preparation thereof according to claim 53, to produce amplified DNA.

### Claim 65

A variant protein, comprising: an amino acid sequence with at least 90% but less than 100% sequence identity to any of SEQ ID NOs:1-23, wherein the variant protein further comprises at least one mutated amino acid having a position corresponding to SEQ ID NO:1 selected from the group of mutated amino acids consisting of (a)-(f) where the mutations in (a)-(f) are:
(a) A1E, G3(K, E or D), K5(L, A or V), E8(M or A), E9D, M10I, A13(D, E, T or V), I14D, V15A, V17(T, E or G), I18V;
(b) E20(M or D) M34(Q or L), E36D, I46F, L48(N or I), M57(L or I), P59(T or A), T61L, D65S, S66(F, E or P);
(c) Q67A, L69(V or K), A73E, M81V, A84R, V88(A or I), R99V, A102D, N113A, D117(T, S or A), A118D, G119(D or E), I121(A or V), V124K, E131H, S135(E or P), V144A, S147(P or A), L148(D or V), Q152(L or P);
(d) T153(A or V), Q170(R or E), M173(L or I), D175E, N178(E, K or R), Q183(L, E or R), L185F, T186(L or I), K187(E or D), Q190(L or M);
(e) A193(I or S), A194(L, S or T), N205(D or K), S216(L or E), R223(V, K or G), A224E, I225(Q or V), V247L, R307H, M316R; and
(f) A330T, D357L, D378N, D380E, I383A, Q387R, L390M; 1400V, E406D, A410S, N411R, A433S, N437G, T439K, A452E, Q459(R or E), N463(V, E or D), L484D, D486E, V494L, T501M, Q530R, I552M, E557(K, Q or R) and T568(E or R).

### Claim 66 (depends on 65)

The variant protein according to claim 65, further comprising at least one amino acid mutation selected from each of groups (a)-(f).

### Claim 67 (depends on 65)

The variant protein according to claim 65, further comprising at least one amino acid motif or at least two amino acid motifs selected from the group consisting of: 3 . . . EEK . . . 5, 15 . . . ADE . . . 17, 65 . . . SPQ . . . 67, 86 . . . RAI . . . 88, 185 . . . LTE . . . 187, 186 . . . TEL . . . 188, 222 . . . LKE . . . 224, 306 . . . VHP . . . 308, 314 . . . HTR . . . 316, 555 . . . LCK . . . 557, 556 . . . CKL . . . 558 and 567 . . . VEL . . . 569.

### Claim 68 (depends on 65)

A variant protein according to claim 65, further comprising two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty mutations at the same position as the corresponding mutant amino acids in (a)-(f) of SEQ ID NO:1.

### Claim 69

A non-naturally occurring synthetic protein, comprising: a fragment 1, a fragment 2, a fragment 3, a fragment 4, a fragment 5, a fragment 6, a fragment 7 and a fragment 8 wherein the fragments are covalently linked, and wherein:
the fragment 1 is selected from Segment 1 having an amino acid sequence selected from the group consisting of SEQ ID NOs:24-39;
the fragment 2 is selected from Segment 2 having an amino acid sequence selected from the group consisting of SEQ ID NOs:40-56;
the fragment 3 is selected from Segment 3 having an amino acid sequence selected from the group consisting of SEQ ID NOs:57-72;
the fragment 4 is selected from Segment 4 having an amino acid sequence selected from the group consisting of SEQ ID NOs:73-87;
the fragment 5 selected from Segment 5 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 88-99;
the fragment 6 selected from Segment 6 having an amino acid sequence selected from the group consisting of SEQ ID NOs:100-111;
the fragment 7 selected from Segment 7 having an amino acid sequence selected from the group consisting of SEQ ID NOs:112-125;
the fragment 8 selected from Segment 8 having an amino acid sequence selected from the group consisting of SEQ ID NOs:126-138; and
wherein the covalently linked fragments having an amino acid sequence that does not have 100% identity to SEQ ID NOs:1-23.

### Claim 70 (depends on 69)

A synthetic protein according to claim 69, wherein the amino acid sequence of the synthetic protein comprises at least one amino acid sequence motif selected from the group consisting of: 3 . . . EEK . . . 5, 15 . . . ADE . . . 17, 65 . . . SPQ . . . 67, 86 . . . RAI . . . 88, 185 . . . LTE . . . 187, 186 . . . TEL . . . 188, 222 . . . LKE . . . 224, 306 . . . VHP . . . 308, 314 . . . HTR . . . 316, 555 . . . LCK . . . 557, 556 . . . CKL . . . 558 and 567 . . . VEL . . . 569.

### Claim 71 (depends on 69)

The synthetic protein of claim 69, wherein the amino acid sequence comprises at least two or three or four or five or six or seven or eight or nine or ten or eleven or twelve of the amino acid sequence motifs selected from the group consisting of: 3 . . . EEK . . . 5, 15 . . . ADE . . . 17 65 . . . SPQ . . . 67, 86 . . . RAI . . . 88, 185 . . . LTE . . . 187, 186 . . . TEL . . . 188, 222 . . . LKE . . . 224, 306 . . . VHP . . . 308, 314 . . . HTR . . . 316, 555 . . . LCK . . . 557, 556 . . . CKL . . . 558 and 567 . . . VEL . . . 569.

### Claim 72

A protein comprising at least 90% sequence identity with SEQ ID NO:1 and further comprising one or more mutations (such as, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, or 79 mutations) selected from the group consisting of: A1E, G3(K, E or D), K5(L, A or V), E8(M or A), E9D, M10I, A13(D, E, T or V), I14D, V15A, V17(T, E or G), I18V, E20(M or D) M34(Q or L), E36D, I46F, L48(N or I), M57(L or I), P59(T or A), T61L, D65S, S66(F, E or P), Q67A, L69(V or K), A73E, M81V, A84R, V88(A or I), R99V, A102D, N113A, D117(T, S or A), A118D, G119(D or E), I121(A or V), V124K, E131H, 5135(E or P), V144A, 5147(P or A), L148(D or V), Q152(L or P), T153(A or V), Q170(R or E), M173(L or I), D175E, N178(E, K or R), Q183(L, E or R), L185F, T186(L or I), K187(E or D), Q190(L or M), A193(I or S), A194(L, S or T), N205(D or K), 5216(L or E), R223(V, K or G), A224E, I225(Q or V), V247L, R307H, M316R, A330T, D357L, D378N, D380E, I383A, Q387R, L390M, 1400V, E406D, A410S, N411R, A433S, N437G, T439K, A452E, Q459(R or E), N463(V, E or D), L484D, D486E, V494L, T501M, Q530R, I552M, E557(K, Q or R) and T568(E or R); and optionally a sequence motif at a specified position in SEQ ID NO:1 selected from the group consisting of: 3 . . . EEK . . . 5, 15 . . . ADE . . . 17, 65 . . . SPQ . . . 67, 86 . . . RAI . . . 88, 185 . . . LTE . . . 187, 186 . . . TEL . . . 188, 222 . . . LKE . . . 224, 306 . . . VHP . . . 308, 314 . . . HTR . . . 316, 555 . . . LCK . . . 557, 556 . . . CKL . . . 558 and 567 . . . VEL . . . 569.

### Claim 73 (depends on 72)

A DNA polymerase according to claim 72, containing at least 12 artificially introduced single amino acid mutations that occur in a three amino acid motif that differs from an amino acid in the corresponding site of a naturally occurring Bst polymerase.

### Claim 74 (depends on 72)

A DNA polymerase according to claim 72, having one or more improved properties for isothermal amplification compared with SEQ ID NO:1, selected from the group consisting of:
(a) an increased reaction speed in the range where the increase is at least 10% and as much as 20%; 500% or 1000%;
(b) an increased temperature stability in the range of 50° C. to 100° C., 50° C. to 90° C. or 60° C. to 90° C.;
(c) an increased salt tolerance in the range of 10 mM-1 M, or 20 mM-200 mM or 500 mM monovalent salt;
(d) an increased storage stability at 25° C., retaining at least 50% activity over 45 weeks, over 1 year or over 2 years;
(e) an enhanced dUTP tolerance of the range of an increase of 50% to 100% dUTP; and
(f) an increased reverse transcriptase activity by at least 2 fold.
